<DOC>
	<DOCNO>NCT01791842</DOCNO>
	<brief_summary>Bone pain due fibrous dysplasia bone usually treat bisphosphonates . A small proportion patient fail respond adequately . Mutated bone cell produce large amount Interleukin-6 ( IL-6 ) , increase bone resorption result . Inhibition IL-6 may interest reduce bone resorption therefore bone pain . TOCIDYS placebo-controlled randomize cross-over trial test hypothesis tocilizumab reduce bone resorption patient fibrous dysplasia already receive bisphosphonates .</brief_summary>
	<brief_title>TOCILIZUMAB IN FIBROUS DYSPLASIA OF BONE</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Fibrous Dysplasia Bone</mesh_term>
	<criteria>fibrous dysplasia bone previously treat IV bisphosphonates persistent bone pain increase bone remodel Chronic renal failure serious infectious disease liver enzymes abnormality pregnancy dyslipidemia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>fibrous dysplasia bone</keyword>
	<keyword>tocilizumab</keyword>
	<keyword>McCune-Albright syndrome</keyword>
</DOC>